Dental products company Envista Holdings (NYSE: NVST) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $669.9 million. Its non-GAAP profit of $0.32 per share was 16% above analysts’ consensus estimates.

Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Envista’s third quarter results exceeded Wall Street’s expectations, with management attributing performance to broad-based growth across its core businesses and a significant margin expansion. CEO Paul Keel highlighted balanced contributions from both volume and pricing, with all major segments—orthodontics, consumables, diagnostics, and implants—delivering growth. Notably, margin improvements were supported by productivity initiatives and the Spark aligner business reaching positive operating profit for the first time. Management also credited recent product launches and increased investment in R&D and sales for fueling momentum.

Looking ahead, Envista’s updated outlook is shaped by ongoing investments in product development, targeted commercial expansion, and disciplined cost management. CFO Eric Hammes emphasized the company’s intent to balance further margin improvements with continued reinvestment into sales and R&D, particularly as new products ramp and tariffs remain a factor. Management signaled confidence that these efforts, alongside stable end-market demand and operational efficiencies, will support sustained core growth and profitability, stating, “We have the ability to get leverage as we work from growth down through the bottom lines of the P&L.”

Key Insights from Management’s Remarks

Management cited a combination of successful new product introductions, productivity gains, and positive end-market dynamics as the main drivers behind the quarter’s outperformance and margin expansion.

• Spark aligner profitability milestone: Envista’s Spark aligner business achieved positive operating profit, a milestone that CEO Paul Keel described as six years in the making. This was driven by consistent unit cost reductions, improved workflow efficiencies, and the benefits of offering both fixed and aligner orthodontic solutions to customers. Management believes Spark’s margins will eventually match company averages, with scale economies and integrated commercial efforts supporting future gains.

• New product launches boost traction: Major launches in the quarter included Spark Jr. (for younger patients), Spark StageRx (a digital workflow platform), Orascoptic Ergo Zoom (an ergonomic loupe system), and DEXIS Imprevo IOS (advanced intraoral scanner). These introductions, along with previously launched products, contributed to momentum, especially in orthodontics and diagnostics.

• Broad-based business growth: All major business lines—ortho, consumables, diagnostics, and implants—delivered growth in the quarter. Consumables saw double-digit growth, buoyed by strong infection prevention products and robust demand from dental service organizations (DSOs), while the implants segment posted a fourth consecutive quarter of global growth.

• Operational improvements and cost discipline: Envista reported ongoing productivity gains, particularly in general and administrative (G&A) expense reductions, which allowed reinvestment into R&D and commercial activities. The company continued to deploy its continuous improvement methodology (EBS) and broke ground on new facilities to support future innovation.

• Tariff and China market dynamics: Management addressed the fluid tariff environment, noting increased costs but reaffirmed the company’s ability to offset these pressures through operational actions. In China, preparations for value-based procurement (VBP) in orthodontics and potential VBP for implants have led to inventory adjustments and cautious volume outlooks, but management views these challenges as manageable.

Drivers of Future Performance

Envista’s forward outlook hinges on the successful scaling of recent product launches, disciplined cost management, and navigating evolving market dynamics, particularly tariffs and international regulatory changes.

• Product innovation and market rollout: Management expects sustained growth from recently launched products across orthodontics, diagnostics, and implants, with further market expansion planned for Spark and digital platforms. CEO Paul Keel stated that new offerings are “striking a chord with customers,” and the company anticipates continued share gains, especially as product adoption broadens geographically.

• Margin management amid tariffs: CFO Eric Hammes outlined a strategy to maintain adjusted EBITDA margins near 14%, despite ongoing tariff headwinds, by offsetting increased costs with operational efficiencies and selective reinvestment into growth areas. The company’s ability to mitigate margin pressure will be a key determinant of near-term profitability.

• China policy and inventory risk: Management highlighted that regulatory changes in China, such as value-based procurement, create uncertainty around revenue timing and inventory levels. While these headwinds are expected to be less severe than previous rounds, the company’s guidance factors in potential inventory drawdowns and margin impacts, particularly in the implant segment.

Catalysts in Upcoming Quarters

Looking forward, we will closely watch (1) the pace of adoption and market penetration for new product launches such as Spark Jr. and DEXIS Imprevo IOS, (2) management’s ability to sustain margin improvements while absorbing tariff and regulatory shifts, and (3) developments in China regarding value-based procurement for implants and orthodontics. Execution on operational initiatives and further gains in key accounts, especially with DSOs and international partners, will also be important indicators of future performance.

Envista currently trades at $20.10, in line with $19.98 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.